Who founded Korro Bio?

Korro Bio was founded by Nessan Bermingham, Jean-François Formela in 2018.

Who are Korro Bio's investors?

Korro Bio's investors include Atlas Venture, MC Healthcare Ventures, New Enterprise Associates (NEA), Alexandria, Qiming Venture Partners, Qiming Venture Partners USA, Rock Springs Capital, Sixty Degree Capital and 2 more.

How much funding has Korro Bio raised?

Korro Bio has disclosed $4M raised across 1 of its 5 known rounds.

Where is Korro Bio headquartered?

Korro Bio is headquartered in Cambridge, US.

Korro Bio

NASDAQ: KRRO

Cambridge, US · Founded 2018 · Delaware corporation · 77 employees on LinkedIn · 17 known investors

Find your way into Korro Bio

Paths you didn't know you had: your email and LinkedIn already hold routes to the Korro Bio team. We find them for you
2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone

Days of research, done the moment you sign in, with every route ranked by how warm it is.

Korro Bio is a biotechnology company developing a new class of RNA-editing therapies guided by human genetics and disease biology. It aims to create genetic medicines for patients with rare and highly prevalent debilitating or life-threatening diseases.

Biotech Healthtech

Founders & leadership

Korro Bio was founded in 2018 by Nessan Bermingham and Jean-François Formela.

Nessan Bermingham Founder & Exec ChairNessan Bermingham has spent nearly three decades in life sciences, founding and leading multiple biotechnology companies including Intellia Therapeutics (which went public), as well as Korro Bio, Stylus Medicine, Liberate Bio, Excelsior Sciences, and EveryOne Medicines, with expertise spanning gene editing, RNA therapeutics, cell therapy, and drug discovery.

Jean-François Formela Co-founderPartner at Atlas Venture

Ommer Chohan Mr. Chohan is the Secretary and Treasurer of the Issuer.CFO at Atlas Venture

Ram Aiyar Chief Executive OfficerHe brings experience in drug development, financial analysis, and healthcare entrepreneurship, with a background in building multidisciplinary teams for therapeutic programs and developing commercial strategies for healthcare startups.

Todd Chappell Chief Operating OfficerHe holds a B.S. in biology from UCLA and an MBA from Boston University, and has spent fifteen years in molecular biology research and life sciences business strategy.

Investors · 17

Atlas Venturelisted by Atlas VentureCambridge · $500K – $1Mvia Jean-François Formela · board

How we know: Atlas Venture's portfolio page · a partner's Signal profile · board seat on SEC Form D · pulse2.com · the VCSheet dataset · open dataset · 5k.vc investor directory · Not right? Tell us

MC Healthcare Ventureslisted by MC Healthcare VenturesCambridge

How we know: MC Healthcare Ventures's portfolio page · Not right? Tell us

New Enterprise Associates (NEA)listed by New Enterprise Associates (NEA)Menlo Park · $200K – $40M

How we know: pulse2.com · Not right? Tell us

AlexandriareportedPasadena

How we know: the S-1 prospectus · pulse2.com · Not right? Tell us

Qiming Venture PartnersreportedBeijing

How we know: open dataset · 5k.vc investor directory · Not right? Tell us

Qiming Venture Partners USAreportedCambridge

How we know: pulse2.com · Not right? Tell us

Rock Springs CapitalreportedBaltimore

How we know: globalgenes.org · Not right? Tell us

Sixty Degree CapitalreportedNorth York

How we know: open dataset · 5k.vc investor directory · Not right? Tell us

Taiwania CapitalreportedTaipei

How we know: the S-1 prospectus · Not right? Tell us

Wu Capitalreported

How we know: pulse2.com · Not right? Tell us

Also in the syndicate · 7

Blue Owl Healthcare OpportunitiesCormorant Asset ManagementDeep Track CapitalleadMP Healthcare Venture ManagementSurveyor Capital (a Citadel company)Tri Locum PartnersVenrock Healthcare Partnerslead

Funding

SEC filings, press & company announcements

$4M disclosed across 1 of 5 rounds · 2019–2026

Undisclosed amountPIPEApr 2026 · 2 sources
Deep Track Capital (lead), Venrock Healthcare Partners (lead), Atlas Venture, Blue Owl Healthcare Opportunities, NEA, Rock Springs Capital, Tri Locum Partners
Source ↗
Undisclosed amountSeries ASep 2020
Wu Capital (lead), Alexandria Venture Investments, Atlas Venture, Cormorant Asset Management, MP Healthcare Venture Management, New Enterprise Associates, Qiming Venture Partners USA, Surveyor Capital (a Citadel company)
Source ↗

▶$4MraisedJun 2019 · 1 investors · Biotechnology

Rule 506(b)

Officers, directors & promoters on the filing

Nessan BerminghamExecutive Officer, Director, Promoter
Ommer ChohanExecutive Officer, Director, Promoter
Jean-Francois FormelaDirector

Offering amount: $4M
Amount sold: $4M
First sale: May 2019
Incorporated: Corporation, Delaware, 2018
Federal exemptions: 06b

Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Founder mafia

4 people who came through Korro Bio went on to found or lead other companies.

Nessan BerminghamMr. Bermingham is the Executive Chair of the Issuer.Founded Intellia Therapeutics +1 Stuart MilsteinVice President Platform BiologyFounded Aerska Andrew FraleyFounder & CTOFounded Judo Bio Ram AiyarChief Executive Officer, President and DirectorFounded Corvidia Therapeutics

Related companies · 4

BridgebioBridgeBio develops treatments for genetic conditions and cancers using a decentralized hub-and-spoke model, where autonomous teams focus on specific diseases or drug candidates while a central hub provides clinical, regulatory, and commercial support. The company partners with academic institutions to advance early-stage research toward late-stage clinical trials.

bioBIO is the world's largest advocacy association representing biotechnology companies and research institutions across the United States and 30+ other nations. The organization facilitates industry networking through events, conferences, and partnering software while providing cost-savings programs and advocacy services for member companies.

RobinhoodRobinhood is a financial trading platform that enables users to manage portfolios across stocks, ETFs, cryptocurrencies, options, futures, and prediction markets. The platform serves retail investors with low barriers to entry, offering portfolio management services and market insights.

NasdaqNasdaq operates a technology infrastructure platform for financial markets across three business segments: Capital Access Platforms (which includes listing services, indices, and analytics tools), Financial Technology (comprising compliance, regulatory, and capital markets software), and Market Services (equities and derivatives trading operations). The company serves financial institutions, listed companies, investment managers, and regulatory agencies globally.

Companies working in the same space as Korro Bio.

Frequently asked questions

What does Korro Bio do?: Korro Bio is a biotechnology company developing a new class of RNA-editing therapies guided by human genetics and disease biology. It aims to create genetic medicines for patients with rare and highly prevalent debilitating or life-threatening diseases.
Who founded Korro Bio?: Korro Bio was founded by Nessan Bermingham, Jean-François Formela in 2018.
Who are Korro Bio's investors?: Korro Bio's investors include Atlas Venture, MC Healthcare Ventures, New Enterprise Associates (NEA), Alexandria, Qiming Venture Partners, Qiming Venture Partners USA, Rock Springs Capital, Sixty Degree Capital and 2 more.
How much funding has Korro Bio raised?: Korro Bio has disclosed $4M raised across 1 of its 5 known rounds.
Where is Korro Bio headquartered?: Korro Bio is headquartered in Cambridge, US.